Spectrum Terminates Ozarelix Development Program in BPH

Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, Wednesday announced that it is discontinuing development of ozarelix in benign prostatic hypertrophy (BPH).
GEN